谷歌浏览器插件
订阅小程序
在清言上使用

Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report

JTO Clinical and Research Reports(2023)

引用 1|浏览21
暂无评分
摘要
ROS1 tyrosine kinase inhibitors (TKIs) were found to provide a substantial clinical benefit for patients with advanced ROS1-positive (ROS1+) NSCLC. Nevertheless, TKI resistance inevitably develops with different mechanisms, preventing prolonged responses. For this reason, next-generation compounds are under clinical development. ROS1 F2004 substitutions have been previously detected on circulating tumor DNA of patients progressing to entrectinib. Hereby, we report the case of a patient with ROS1+ NSCLC in which F2004V-acquired mutation was detected on a site of disease progression, after entrectinib and crizotinib failure. A subsequent treatment with next-generation TKI repotrectinib led to disease response, providing the first clinical evidence of activity of repotrectinib against F2004V resistance mutation.
更多
查看译文
关键词
lung cancer,resistance mutation,non-small
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要